Reliability of two different bedside assays for C-reactive protein in newborn infants

Enrico Zecca*, Giovanni Barone, Mirta Corsello, Costantino Romagnoli, Eloisa Tiberi, Chiara Tirone and Giovanni Vento
Division of Neonatology, Department of Pediatrics, Catholic University of the Sacred Heart, Rome, Italy

Abstract

Background: Bedside tests for C-reactive protein (CRP) have been studied in pediatric patients, but not in neonates.

Methods: This study compared the results of two rapid bedside tests for CRP (Quick-Read CRP, Orion Diagnostic, Espoo, Finland and NycoCard CRP-Single Test, Axis-Shield, Oslo, Norway) with those of our central laboratory method (CRP-Lab) in newborn infants. CRP concentrations were determined using 72 samples obtained from 43 infants with suspected sepsis occurring between 1 and 28 days of life.

Results: Considering positive CRP concentrations to be ≥10 mg/L, both bedside tests had good specificity (Quick-Read 80.5%, NycoCard 83.3%) and sensitivity (Quick-Read 97.2%, NycoCard 94.4%) when compared with our CRP-Lab. The agreement of measurement with central laboratory values was high for both the bedside tests, without statistically significant differences between the methods. The Quick-Read and NycoCard methods did not show any statistically significant systematic proportional bias when compared with the central laboratory values. The accuracy of the results of both bedside tests is somewhat decreased when CRP concentrations are >100 mg/L.

Conclusions: This study shows that both the Quick-Read and the NycoCard test can be used for serial determinations of CRP concentrations in newborn infants. They require small volumes of blood and provide reliable results in <5 min.


Keywords: bedside testing; C-reactive protein; newborn infant; sensitivity and specificity; sepsis.

Introduction

Neonatal sepsis is a systemic disease, characterized by massive microbial invasion followed by a systemic inflammatory response (1–3). It affects 15%-30% of newborn infants admitted to the neonatal intensive care unit, particularly very low birth weight infants, with high mortality (2). Because the suspicion of sepsis in the neonate is often based on non-specific clinical signs, several predictive laboratory parameters have been investigated, including white blood cell count, tumor necrosis factor, interleukin-6, serum amyloid A, procalcitonin and C-reactive protein (CRP) (4–8). Serial CRP measurements are also used to monitor the evolution of bacterial diseases because CRP concentration drops quickly in response to effective treatment (9). Monitoring CRP concentration can lead to shorter antibiotic regimens or, alternatively, can alert one to the likelihood of complications and help predict outcome, even earlier than clinical signs (10). Conventional laboratory methods for CRP can be unavailable in urgent situations, or may not provide results in a timely manner. They usually require at least 1 mL of blood and are uncomfortable if used for serial measurements in newborn infants. Rapid bedside quantitative assays for CRP that require insignificant amount of blood have been developed recently. Unfortunately, no data has been published about their use in the neonatal period, apart from the short report by Makhoul and coworkers on late-onset sepsis (11). The aim of this study was to compare the diagnostic accuracy between two rapid bedside tests for CRP compared with the laboratory method, and provide information about their reliability in newborn infants.

Materials and methods

Study population

This prospective observational study was conducted from March to September 2008, in the Division of Neonatology at our University Hospital. The study was approved by our Institutional Ethical Board. We included all newborns who developed clinically suspected sepsis during the first month of life. Infants were confined to open cots or incubators, depending on their weight. For each infant we collected gestational age, birth weight, age and weight when sepsis was first suspected, hematocrit and CRP values. Work-up for sepsis included blood, urine and cerebrospinal fluid cultures for all infants. Culture of bronchoalveolar lavage fluid was also performed in infants that were ventilated.

Laboratory methods

A 1 mL blood sample was drawn from the peripheral vein for CRP measurements. CRP was measured on the same sample, using our central laboratory method (CRP-Lab) and two different bedside tests, each requiring ~3 min to obtain the result. Our central laboratory measures CRP by the...
CardioPhase hsCRP on BN II System (Dade Behring, Newark, NJ, USA) which is a particle enhanced immunoturbidimetric method requiring 1 mL of whole blood. Due to organizational considerations, our central laboratory gives us the result in ~24 h, even though this method requires only 6 min to perform. The result is evaluated by comparison to a standard with a known CRP concentration. The assigned value of CRP in N Rheumatology Standard SL is traceable to the international reference preparation BCR-CRM 470 (12). The lower limit of detection for CRP for our laboratory is 0.175 mg/L. The Quick-Read CRP (CRP-Q; Orion Diagnostic, Espoo, Finland) is an immunoturbidimetric assay based on microparticles coated with anti-human CRP. This method measures the change in turbidity of the solution caused by the reaction of the particles and CRP in the sample. It requires 20 μL of whole blood and provides results in 2 min, with an analytical measurement range of 8–160 mg/L. The NycoCard CRP-single test (CRP-N; Axis-Shield, Oslo, Norway) is a solid phase, sandwich-format, immunometric assay requiring only 5 μL of whole blood. In the test well of the device a membrane is coated with immobilized CRP-specific monoclonal antibodies. When the sample flows through the membrane, CRP is captured by the antibodies in a sandwich-type reaction. The membrane changes color in the presence of pathological concentrations of CRP. The instrument quantitatively measures the color intensity in 3 min with an analytical measurement range of 8–200 mg/L. As recommended by the manufacturer, all results obtained with the two bedside assays were corrected for hematocrit values that deviated from 40%, using a fixed table provided by the manufacturer. A coefficient of variation of 7% was observed at a CRP concentration of 0.41 mg/L for the CRP-Lab, and at a CRP concentration of 12 mg/L for the bedside tests.

Statistics

Sensitivity, specificity, positive and negative predictive values were calculated comparing all the measurements obtained by the bedside tests (CRP-Q Quick-Read test; CRP-N NycoCard test) with those performed in the CRP-Lab. CRP values ≥10 mg/L were considered as positive for all three tests. Considering only positive CRP values, we evaluated the agreement of measurements between each bedside test and the central laboratory test using Passing-Bablok non-parametric regression. The regression equation was expressed with the 95% confidence interval (CI) for the estimates of the slope and intercept. The Bland-Altman plot was chosen to visualize the agreement between each bedside test and the CRP-Lab. We performed univariate linear regression to verify the possible influence of some factors on the difference between each of the methods investigated and the CRP-Lab. Variables included in the model were gestational age, birth weight, age and weight when sepsis was suspected, hematocrit and CRP values. The coefficient of determination ($r^2$) was used to check for the goodness of fit. Only those variables with a $p < 0.25$ were considered for multiple linear regression analysis. Statistical analyses were performed with Microsoft Excel 2003, SPSS for Windows rel. 17.0 (SPSS, Inc., Chicago, IL, USA) and Medcalc software rel. 9.3.7.0 (Medcalc, Mariakerke, Belgium). A $p < 0.05$ was considered for statistical significance.

**Table 1** Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) for the two bedside tests, assessed in comparison with central laboratory CRP concentrations ≥10 mg/L.

<table>
<thead>
<tr>
<th>Test</th>
<th>Sensitivity, %</th>
<th>Specificity, %</th>
<th>PPV, %</th>
<th>NPV, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quick-Read CRP</td>
<td>97.2</td>
<td>80.6</td>
<td>83.3</td>
<td>96.7</td>
</tr>
<tr>
<td>NycoCard CRP single test</td>
<td>94.4</td>
<td>83.3</td>
<td>85.0</td>
<td>93.8</td>
</tr>
</tbody>
</table>

**Figure 1** Passing-Bablok regression analysis between the central laboratory method and the two bedside tests. The analysis includes 36 samples with CRP-Lab concentrations ≥10 mg/L. CRP values expressed as mg/L. The solid and dashed lines indicate the regression line and confidence interval for the regression line, respectively. CRP-Lab, central laboratory method; CRP-Q, Quick-Read test; CRP-N, NycoCard test.
Results

A total of 72 blood samples were obtained for measurement of CRP concentrations. These samples were collected from 43 infants during 52 episodes of work-up of suspected sepsis performed between 1 and 28 days of life (median 11, interquartile range 5–22 days). Gestational age and birth weight of the 43 infants were 33 ± 5 weeks (range 25–41 weeks) and 2250 ± 950 g (range 510–4180 g).

In the 36 samples with CRP-Lab concentrations ≥ 10 mg/L only one had CRP-Q < 10 mg/L and two had CRP-N < 10 mg/L. In the 36 samples with CRP-Lab levels < 10 mg/L, seven had a CRP-Q > 10 mg/L and six had a CRP-N > 10 mg/L. The specificity, sensitivity and predictive values are shown in Table 1.

Passing-Bablok regression yielded an equation of \( y = 1.0734x + 1.8110 \) for CRP-Q and \( y = 0.8759x + 0.9522 \) for CRP-N (see Figure 1). The slope and the intercept were not significantly different from 1 and 0, respectively. The Cusum test confirmed no significant deviation from linearity \( (p > 0.10) \). Bias for both assays vs. CRP-Lab was evaluated using Bland-Altman plots and is shown in Figure 2. The average bias values were determined to be 5.8 mg/L (95% CI 1–19 to 13.4) for CRP-Q and −5.7 mg/L (95% CI −12.6 to 1.2) for CRP-N. This means that Quick-Read and NycoCard had no statistically significant systematic proportional bias. The Bland-Altman plots also showed that the reliability of both bedside tests decreased with increases in CRP-Lab values. Univariate linear regression confirmed that the difference between each of the methods investigated and the CRP-Lab is affected by the highest CRP-Lab values only, and this was a bit more evident for CRP-N \( (r^2 = 0.4693) \) than for CRP-Q \( (r^2 = 0.3052) \). We did not perform multivariate regression analysis because no other variables reached \( p < 0.25 \) in the univariate analysis.

Discussion

Sepsis remains one of the main causes of neonatal morbidity and mortality and is particularly true for very low birth weight infants (13, 14). In the study published by Stoll and coworkers in 2002, of 6215 very low birth infants who survived beyond 3 days, 21% had one or more episodes of sepsis with a mortality rate of 18% (14). Antimicrobial treatment is often started on the basis of non-specific clinical signs because an early diagnosis can be crucial to optimize patient outcome. This attitude implies a widespread tendency for antibiotic abuse with the consequent risk of antimicrobial resistance. Between the several laboratory parameters that are predictive of sepsis, CRP has been thoroughly investigated because it can be detected within 6–12 h following the onset of the inflammatory process, and it peaks more quickly than other acute phase reactants (15, 16). However, the amount of blood and the time to obtain results from the central laboratory can constitute important limitations to serial CRP measurements in neonates with suspected sepsis. Despite the development of rapid quantitative bedside assays for CRP requiring an insignificant amount of blood, the short report by Makhoul and coworkers on late-onset sepsis is the only one published about their use in the neonatal period (11). Some authors studied the usefulness of CRP determinations in neonatal sepsis, but they did not use bedside tests (4, 8, 17, 18). Others studied bedside tests in pediatric patients, but not in neonates (19–22). For these reasons, we designed this prospective study to compare the diagnostic accuracy between two rapid bedside tests for CRP compared with a laboratory method and to provide information concerning their reliability in newborn infants.

Considering CRP values ≥ 10 mg/L to be positive, both bedside tests have good specificity (Quick-Read 80.5%, NycoCard 83.3%), and an even better sensitivity (Quick-Read 97.2%, NycoCard 94.4%), when compared with our CRP-Lab. The agreement of measurement with the central laboratory values as estimated by Passing-Bablok analysis is high for both the bedside tests, without significant differences between them. The slope was 1.0734 for Quick-Read and
0.8759 for NycoCard. Both Passing-Bablok regression and Bland-Altman analysis showed that Quick-Read and NycoCard have no statistically significant systematic proportional bias. Univariate regression analysis showed that gestational age, birth weight, hematocrit and day of life have no influence on the agreement of measurement between the bedside tests and the central laboratory assay. The accuracy of measurements for both the bedside tests is affected only by very high CRP concentrations (> 100 mg/L). This finding was more evident for the NycoCard than for the Quick-Read test. Interestingly, this observation is in agreement with that of Cohen et al. (20) who found relevant quantitative discrepancies between the CRP-N and their CRP-Lab for CRP concentrations >150 mg/L. However, this limitation is of little clinical relevance considering that only four out of 72 of our study samples showed CRP concentrations > 100 mg/L.

In conclusion, we provide evidence that both the Quick-Read test and the NycoCard test have excellent correlation with a validated CRP assay in newborn infants. They have high sensitivity and specificity, require a very small amount of blood, and are easy to use at the bedside of the patient. Also, they provide highly reliable results in <5 min. These characteristics allow them to be used for serial determinations of CRP concentrations in newborn infants, and can be of great help for clinicians for diagnosing and managing neonatal sepsis.

Conflict of interest statement

The authors disclaim any conflict of interest. The authors did not accept any funding or support from organizations that may in any way gain or lose financially from the results of our study. None of the authors has been ever employed by organizations that may in any way gain or lose financially from the results of this study.

References